VivoSeq
Infectious Disease

Appendicitis

48

Pipeline Programs

10

Active Trials

13

Companies Involved

Appendicitis is a moderately active landscape with 48 programs across 13 companies. The most active players are Melinta Therapeutics, Inc., Eyegate Pharmaceuticals, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd.. 16 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

11/100

Mech. Concentration

30/100

Completion Rate

85/100

Attrition Rate

10/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

59

clinical trials

Completed35 · 59%
Unknown status8 · 14%
Active, not recruiting4 · 7%
Recruiting4 · 7%
Withdrawn3 · 5%
Terminated3 · 5%
Other2 · 3%

Trial Activity

59 trials

Antibiotics vs Surgery in Acute Appendicitis
Active, not recruiting··N/A·NCT07492329·400 enrolled
The Role of Contrast Enhanced Ultrasound in Appendicitis
Completed··Phase 2·NCT03687502·37 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)